focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,783.50
Bid: 1,780.00
Ask: 1,780.50
Change: -29.00 (-1.60%)
Spread: 0.50 (0.028%)
Open: 1,792.50
High: 1,802.00
Low: 1,775.50
Prev. Close: 1,812.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Strong US data, Wall Street earnings lift stocks

Thu, 15th Apr 2021 16:56

(Alliance News) - Stock prices in London ended higher on Thursday, with miners helping to lift the FTSE 100 and GlaxoSmithKline posting hefty share price gains, though Deliveroo failed to inspire with its maiden trading update as a listed company.

Across the Atlantic, focus was on strong US retail sales numbers and falling jobless claims figures, while the Wall Street corporate earnings calendar continued with updates from Citigroup, Bank of America and PepsiCo.

The FTSE 100 index rose 43.92 points, or 0.6%, to close at 6,983.50. The mid-cap FTSE 250 ended the session 116.59 points, or 0.5%, higher at 22,472.04.

The mid-cap index hit another record closing high, while the blue-chip counterpart edges closer to 7,000 points, levels last seen in February 2020.

The AIM All-Share index closed up 4.22 points, 0.3%, at 1,248.13 on Thursday.

The Cboe UK 100 index ended up 0.7% at 695.73. The Cboe 250 closed up 0.6% at 20,096.78. The Cboe Small Companies closed up 1.0% at 14,567.33.

"European stocks are charging higher after the US earning season kicked off on the right foot. US banks are often considered a proxy for the broader economy. As a result, their earnings are strong drivers of sentiment," OANDA analyst Sophie Griffiths noted.

On Wall Street, the Dow Jones Industrial Average was up 0.8% shortly before the market close in London. The S&P 500 rose 0.9% and the Nasdaq Composite jumped 1.0%.

Bank of America said it expects an accelerated recovery going forward as its income increased in the first quarter of 2021. In addition, the North Carolina, US-based bank said it will repurchase up to USD25 billion of stock over time.

Revenue in the three months to the end of March slipped to USD8.07 billion from USD9.13 billion the year before, but pretax income rose to USD871 million versus USD582 million the year prior.

BofA lowered its provision for credit losses by a massive USD6.6 billion to a benefit of USD1.9 billion.

Citigroup reported growth in earnings in the first quarter - thanks to credit releases - and has set out to restructure its underperforming Global Consumer Banking unit by "doubling down" on its wealth business.

In the three months to March 31, the New York-headquartered universal bank saw net income more than triple to USD7.94 billion from USD2.54 billion.

In New York, BofA shares were down 4.2%, while Citi lost 1.5%.

"The upbeat numbers served to reinforce expectations of a strong US economic recovery. If the world's largest economy is performing well, this is good news for the global economy and risk sentiment," Griffiths added.

Adding to the positive sentiment, US retail sales growth surged in March as government stimulus payments made their way to households. On a monthly basis, US retail sales jumped 9.8% in March, rebounding from a 2.7% fall in February. The figure was well above the market estimate, cited by FXStreet, of 5.9%.

Elsewhere, the Department of Labor said in the week ending April 10, the advance figure for seasonally adjusted initial claims was 576,000, down sharply from 769,000 claims the week before. The latest reading was well below market expectations of 700,000.

In Frankfurt, the DAX 30 ended 0.3% higher, while the CAC 40 rose 0.4%.

The EU said Wednesday that it is expecting 50 million Pfizer coronavirus vaccine doses earlier than expected, as the US said it would continue a pause in vaccinations using the Johnson & Johnson shot for at least another week so regulators can assess possible blood clot links.

The EU's vaccination campaign has picked up speed recently after a difficult beginning.

In London, GlaxoSmithKline ended as one of the best blue-chip performers, up 5.0%.

Activist investor Elliot Management has taken a multi-billion-pound stake in pharmaceutical giant, the Financial Times reported on Thursday.

The FT said Elliot's stake was confirmed by people with knowledge of the investment and is a "significant" position, according to one of them. The newspaper reported that Elliot's investment comes as GSK shareholders have become disillusioned with the leadership of Chief Executive Emma Walmsley.

Miners also rose. Antofagasta added 3.4%, BHP climbed 1.5% and Rio Tinto rose 2.3%.

Metal prices were on the up as the dollar's strength waned and amid expectations of strong economic growth in China.

Gross domestic product data from China is reported overnight on Friday.

Gold was trading at USD1,766.35 an ounce at the London equity market close Thursday, up from USD1,736.27 on Wednesday.

The pound was quoted at USD1.3788 at the London equities close on Thursday, down slightly from USD1.3793 on Wednesday. The euro was priced at USD1.1965, down from USD1.1975. Against the Japanese yen, the dollar was quoted at JPY108.71, down from JPY108.96.

Back in London, Unilever rose 1.1% and in Zurich, Nestle also climbed 0.5%. The duo ended higher after Pepsi reported a sharp rise in income in the first quarter and guided for further growth in the second quarter on vaccination efforts expected to boost the food and beverages industry, especially when people start to travel again.

Pepsi was up 0.5% in New York.

In the three months to March 31, the food, snack, and beverage giant recorded net income of USD1.72 billion, up 27% from USD1.35 billion the year before.

Deliveroo shares fell 3.2% and now sit about a third lower than the IPO price of 390 pence.

Deliveroo maintained its full-year guidance after a sharp acceleration in orders in the first quarter, though cautiously eyed a relaxation of lockdown rules ahead.

In its maiden trading update as a London-listed company, Deliveroo said it made "significant progress" in the first quarter ended March 31, with total orders more than doubling to 71 million from 33 million.

IG Markets analyst Chris Beauchamp commented: "Those hoping for a rebound in Deliveroo shares after the Q1 update this morning have been disappointed afresh, with the shares taking another turn lower despite the anticipated bounce in order volumes.

"Crucially, fears about a changing environment thanks to the end of lockdown restrictions appear to be justified, with the firm leaving guidance unchanged and noting that the end of 'special circumstances' would make it hard to issue accurate forecasts for the coming few months."

Brent oil was trading at USD66.58 a barrel late Thursday, up from USD66.32 late Wednesday.

Friday's economic calendar has a spate of data from China overnight, including the GDP reading, retail sales and industrial output.

Friday's local corporate calendar has a trading statement from emerging markets-focused asset manager Ashmore Group and private hospital operator Mediclinic International. In the US, Morgan Stanley reports first-quarter results.

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more
20 Feb 2024 08:55

IN BRIEF: Diageo welcomes GSK's CFO as non-executive director

Diageo PLC - London-based brewer and distiller sells more than 200 drinks brands, including Guinness stout, Captain Morgan rum and Johnnie Walker whisky - Appoints GSK PLC's chief financial officer and executive director, Julie Brown, as a non-executive director. Says she will succeed Alan Stewart as chair of the audit committee after his retirement following the firm's annual general meeting in September. Chair Javier Ferran says: "Julie brings many years of experience in financial, commercial and strategic roles in international companies operating in highly regulated industries. She is strongly committed to enabling diversity in business and to creating sustainable, long-term value for stakeholders. I look forward to her contribution to Board discussions and to working with her in progressing Diageo's ambition to be one of the most trusted and respected consumer products companies in the world."

Read more
15 Feb 2024 14:44

UK dividends calendar - next 7 days

Friday 16 February 
JPMorgan Asia Growth & Income PLCdividend payment date
JPMorgan Japan Small Cap Growth & Income PLCdividend payment date
Murray International Trust PLCdividend payment date
Premier Miton Group PLCdividend payment date
Schroder Oriental Income Funddividend payment date
Solid State PLCdividend payment date
Monday 19 February 
no events scheduled 
Tuesday 20 February 
Invesco Bond Income Plus Ltd 
Wednesday 21 February 
no events scheduled 
Thursday 22 February 
abrdn Asia Focus PLCex-dividend payment date
Alumasc Group PLCex-dividend payment date
AstraZeneca PLCex-dividend payment date
BlackRock Throgmorton Trust PLCex-dividend payment date
Braemar PLCex-dividend payment date
easyJet PLCex-dividend payment date
Ecofin US Renewables Infrastructure Trust PLCex-dividend payment date
Endeavour Mining PLCex-dividend payment date
FRP Advisory Group PLCex-dividend payment date
Gateley Holdings PLCex-dividend payment date
GSK PLCex-dividend payment date
Hercules Site Services PLCex-dividend payment date
Jersey Electricity PLCex-dividend payment date
Land Securities Group PLCex-dividend payment date
Molten Ventures VCT PLCex-dividend payment date
Northern Bear PLCex-dividend payment date
Redrow PLCex-dividend payment date
Samuel Heath & Sons PLCex-dividend payment date
Titon Holdings PLCex-dividend payment date
Unilever PLCex-dividend payment date
Van Elle Holdings PLCex-dividend payment date
Virgin Money UK PLCex-dividend payment date
Witan Investment Trust PLCex-dividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
15 Feb 2024 11:02

Berenberg hikes target price on GSK

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker GSK from £16.50 to £18.20 on Thursday, stating the group was moving closer to offsetting losses associated with the expiry of its patent on HIV drug dolutegravir.

Read more
15 Feb 2024 09:45

LONDON BROKER RATINGS: Jefferies cuts Kingfisher but Citi raises

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.